Zobrazeno 1 - 10
of 309
pro vyhledávání: '"Yanqiao, Zhang"'
Autor:
Shuwei Hu, Fathima N. Cassim Bawa, Yingdong Zhu, Xiaoli Pan, Hui Wang, Raja Gopoju, Yanyong Xu, Yanqiao Zhang
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-12 (2024)
Abstract The crosstalk between adipose tissue and the liver is finely controlled to maintain metabolic health. Yet, how adipose tissue controls toxic free fatty acid overflow into the liver remains incompletely understood. Here, we show that adipocyt
Externí odkaz:
https://doaj.org/article/a1c1e6c18b764bafb8515ca34423153b
Autor:
Tianjiao Dang, Xin Guan, Luying Cui, Yuli Ruan, Zhuo Chen, Haoyi Zou, Ya Lan, Chao Liu, Yanqiao Zhang
Publikováno v:
Clinical Epigenetics, Vol 16, Iss 1, Pp 1-13 (2024)
Abstract Colorectal cancer (CRC) is a common malignant tumor with the third and second highest incidence and mortality rates among various malignant tumors. Despite significant advancements in the present therapy for CRC, the majority of CRC cases fe
Externí odkaz:
https://doaj.org/article/669cdd51155a45838c0aa3b0be213766
Autor:
Yu Cheng, Zan Teng, Yanqiao Zhang, Bo Jin, Zhendong Zheng, Li Man, Zhenghua Wang, Yuee Teng, Ping Yu, Jing Shi, Ying Luo, Ying Wang, Jingdong Zhang, Huijuan Zhang, Jiwei Liu, Hao Chen, Jiawen Xiao, Lei Zhao, Lingyun Zhang, Yu Jiang, Ying Chen, Jian Zhang, Chang Wang, Sa Liu, Jinglei Qu, Xiujuan Qu, Yunpeng Liu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Colorectal cancer is the third most common cancer and the second leading cause of cancer death. There are limited therapeutic options for the treatment of locally advanced or metastatic colorectal cancers which fail first-line che
Externí odkaz:
https://doaj.org/article/ee52e0f2ebf947009350b462f2706768
Autor:
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
Publikováno v:
Cancer Communications, Vol 44, Iss 8, Pp 910-914 (2024)
Externí odkaz:
https://doaj.org/article/53acf5bc101a47cdb61c89a6accc0936
Autor:
Dan Liu, Jifang Gong, Muling Liu, Huan Zhou, Shumei Wang, Jian Yang, Chenwei Shang, Xinlei Guo, Cha Wang, Yanqiao Zhang, Lin Shen
Publikováno v:
Cancer Medicine, Vol 13, Iss 22, Pp n/a-n/a (2024)
Abstract Background BC001 is a novel fully human immunoglobulin G1 monoclonal antibody blocking VEGFR2. This phase I study aimed to assess BC001 alone and plus chemotherapy in solid tumors. Methods In dose escalation part, BC001 was assessed at dose
Externí odkaz:
https://doaj.org/article/8608764d1af44672ab2b88e17bdae052
Autor:
Yuli Ruan, Yue Ma, Ming Ma, Chao Liu, Dan Su, Xin Guan, Rui Yang, Hong Wang, Tianqin Li, Yang Zhou, Jianqun Ma, Yanqiao Zhang
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Neoadjuvant immunochemotherapy (NICT) plus esophagectomy has emerged as a promising treatment option for locally advanced esophageal squamous cell carcinoma (LA-ESCC). Pathologic complete response (pCR) is a key indicator associat
Externí odkaz:
https://doaj.org/article/b47d90f9d5124142873c9d103f9f27c5
Autor:
Li Xu, Jinzhang Chen, Chang Liu, Xiaoling Song, Yanqiao Zhang, Haitao Zhao, Sheng Yan, Weidong Jia, Zheng Wu, Yabing Guo, Jiayin Yang, Wei Gong, Yue Ma, Xiaobo Yang, Zhenzhen Gao, Nu Zhang, Xin Zheng, Mengyu Li, Dan Su, Minshan Chen
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Lenvatinib is widely used in treatment of unresectable hepatocellular carcinoma (uHCC), but the benefit of its combination with immunotherapy needs to be verified. This study evaluated the efficacy and safety of tislelizumab plus
Externí odkaz:
https://doaj.org/article/c3ae2efaf43843d5896283b1c2eb7e47
Autor:
Hengzhen Li, Yuli Ruan, Chao Liu, Xiaona Fan, Yuanfei Yao, Yisheng Dai, Yushuai Song, Dan Jiang, Ning Sun, Guangtao Jiao, Zhuo Chen, Shiheng Fan, Fanfei Meng, Huike Yang, Yanqiao Zhang, Zhiwei Li
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Background Activation of VDR pathway was a promising anti-tumor therapy strategy. However, numerous clinical studies have demonstrated the effect of activating VDR is limited, which indicates that VDR plays a complex role in vivos. Methods W
Externí odkaz:
https://doaj.org/article/32e3c4bf88fb4accb048d728d4f4f64c
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Objective AT-rich interaction domain 1A (ARID1A) mutant tumors show active anti-tumor immune response, which is the potential indication of immunotherapy. However, the relationship between the heterogeneous ARID1A expression and the immune r
Externí odkaz:
https://doaj.org/article/53ebfd418e61444584bb0f2d4d19476f
Autor:
Xin Guan, Ruiqi Liu, Bojun Wang, Ruxin Xiong, Luying Cui, Yuanyu Liao, Yuli Ruan, Lin Fang, Xiaolin Lu, Xuefan Yu, Dan Su, Yue Ma, Tianjiao Dang, Zhuo Chen, Yuanfei Yao, Chao Liu, Yanqiao Zhang
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 6, Pp n/a-n/a (2024)
Abstract Background Although numerous studies have indicated that activated pyroptosis can enhance the efficacy of antitumour therapy in several tumours, the precise mechanism of pyroptosis in colorectal cancer (CRC) remains unclear. Methods Pyroptos
Externí odkaz:
https://doaj.org/article/6beb11d974954c529a23288c5ac51a03